White Paper

2-Deoxy-D-Glucose (2-DG) is an anti-viral and anti-inflammatory drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) of Defense Research and the Development Organization (DRDO). Dr. Reddy's collaborated with DRDO to conduct clinical trials for 2-DG in COVID-19 patients. Based on phase II and the phase III studies in India, 2-DG has received an emergency use authorization as an adjunct therapy in moderate to severe COVID-19 patients in the hospital setting.

Dr. Reddy's is the first firm to successfully provide access to 2-DG for COVID-19 patients. As a result, we are able to offer our customers early access to the API and finished formulation for specific markets. Want to know more ? please fill in the contact details to read the whitepaper on our 2 DG API and finished product offerings.